Start Codon and One Nucleus enhance life science ecosystem
Cambridge cluster BioMedTech influencers One Nucleus and Start Codon have fused key resources to reinforce scale-up support for exciting young life sciences businesses in the UK’s leading business, science & technology hotspot.
One Nucleus will support and profile the life science and healthcare start-ups participating in the Start Codon accelerator programme.
Founded in April 2019, Start Codon aims to identify and recruit high potential life science and healthcare companies from across the UK and beyond, provide seed-funding, and leverage the world-class resources of the Cambridge Cluster to reduce risk and prepare them for a successful Series A fundraise.
From January 6, One Nucleus will provide Start Codon cohort companies with gold membership benefits over 12 months focused on raising their profile and helping to access new industry contacts.
Gold membership benefits include an online company profile on One Nucleus’ ‘Member Directory’, discounted training in events such as Genesis and ON Helix, preferred supplier agreement discounts and participation in special interest groups.
Given One Nucleus’ extensive network of life science start-ups, the partnership will also help Start Codon secure disruptive platform technology companies for its programme.
Start Codon CEO Dr Jason Mellad said: “Like Start Codon, One Nucleus is committed to playing an active and supportive role in enabling the success of the UK life science cluster, particularly that in the East of England and London.
“Having One Nucleus membership benefits will be extremely valuable to our cohort, particularly for developing a network of industry leading contacts.”
Tony Jones, CEO at One Nucleus, added: “One Nucleus can provide local, UK-wide and international connectivity to enable companies to maximise their performance within the life sciences and healthcare industry. We are excited to partner with Start Codon to help facilitate the next generation of innovative and entrepreneurial companies.”
Start Codon is a new model of life science and healthcare business accelerator, and the first in Cambridge, to provide companies with a combination of seed funding, facilities, mentoring and access to a dedicated team and network of industry leading contacts. Investors in Start Codon include Cambridge Innovation Capital, the Babraham Research Campus through Babraham Bioscience Technologies, Genentech, a member of the Roche Group, Dr Jonathan Milner and Dr Ian Tomlinson.
Founded to identify ideas that have the potential to impact the diagnosis, prevention and/or treatment of disease, and support their path to successful Series A funding, Start Codon aims to revolutionise the way life science and healthcare innovation is commercialised by reducing risk in investment opportunities and developing companies in the Cambridge cluster that are built to succeed globally.
• PHOTOGRAPH: Start Codon CEO Dr Jason Mellad. Picture by Phil Mynott.